Rallybio Corporation RLYB 深 滬
已收盤 04-02 16:00:00 美东时间
8.43
+0.030
+0.36%
華盛通- 最 高8.45
- 今 開8.24
- 成交量 1.46万股
- 最 低 8.20
- 昨 收 8.40
- 總市值 4459.20万
- 52周最高 11.49
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 1.788
- 委 比 -16.67%
- 總股本 528.97万
- 歷史最高 206.24
- 量 比 0.19
- 振 幅 2.98%
- 歷史最低 1.7608
- 每 手 1
- 風險率 1.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
03-03 04:56
Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism
Rallybio stock jumps after announcing a $505 million merger with Candid Therapeutics, boosting cash to $700 million.
03-02 23:51
Rallybio To Acquire Candid Therapeutics Under All-Stock Merger Agreement
Following closing, pre-Transaction Rallybio equityholders are expected to own approximately 3.65% of the combined company, and pre-Transaction Candid equityholders (inclusive of investors participating in the Financing)
03-02 21:09
Rallybio to acquire Candid Therapeutics in merger deal
Rallybio to acquire Candid Therapeutics in merger deal Rallybio Corporation has agreed to acquire Candid Therapeutics in a merger that would create a combined company operating as Candid Therapeutics and trading on Nasdaq under the ticker CDRX. Candid also secured more than $505 million in concurren
03-02 21:01
Rallybio Reports Results From Phase 1 Confirmatory PK/PD Clinical Trial Evaluating RLYB116 In Development For Patients With Complement-Mediated Diseases With Initial Focus On Immune PTR And Refractory APS
– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases –– Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion Refractoriness
02-17 21:05
Rallybio Reports Positive Phase 1 Results for RLYB116 in Complement-Mediated Diseases
Rallybio Reports Positive Phase 1 Results for RLYB116 in Complement-Mediated Diseases Rallybio Corporation announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic clinical trial evaluating RLYB116, a once-weekly, subcutaneously injected C5 inhibitor in development fo
02-17 21:02
Rallybio Announces 1-For-8 Reverse Stock Split
Rallybio Corporation (NASDAQ:RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio's Amended and Restated Certificate
02-04 05:59
Rallybio Executes 1-for-8 Reverse Stock Split
Rallybio Executes 1-for-8 Reverse Stock Split Rallybio Corporation will implement a one-for-eight reverse stock split of its common stock, effective February 6, 2026. The move aims to increase the per share trading price and help maintain its listing on the Nasdaq Capital Market. After the split, Ra
02-04 05:05
Rallybio führt Aktiensplit im Verhältnis 1:8 durch
Rallybio führt Aktiensplit im Verhältnis 1:8 durch Die Rallybio Corporation führt einen Reverse Stock Split im Verhältnis 1:8 durch. Die Maßnahme tritt am 6. Februar 2026 in Kraft und soll den Aktienkurs anheben, um die Anforderungen für die Notierung am Nasdaq Capital Market zu erfüllen. Die Aktie
02-04 05:05
Rallybio Corporation Held Special Shareholder Meeting
Rallybio Corporation Held Special Shareholder Meeting Rallybio Corporation held a special meeting of stockholders on January 26, 2026. Stockholders voted to approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the company's issued and outstanding common stock a
01-30 06:15
